Depression and impulse control disorders in Parkinson's disease: two sides of the same coin?

Neurosci Biobehav Rev. 2014 Jan:38:60-71. doi: 10.1016/j.neubiorev.2013.11.001. Epub 2013 Nov 12.

Abstract

Depression and impulse control disorders (ICD) are two common neuropsychiatric features in Parkinson's disease (PD). Studies have revealed that both phenomena are associated with aberrations in ventral striatal dopamine signaling and concomitant dysfunction of the reward-related (limbic) cortico-striatal-thalamocortical (CSTC) circuit. Depression in PD seems associated with decreased activity in the limbic CSTC circuit, whereas ICD seem associated with increased limbic CSTC circuit activity, usually after commencing dopamine replacement therapy (DRT). Not all DRT using PD patients, however, develop symptoms of ICD, suggesting an additional underlying neurobiological susceptibility. Furthermore, the symptoms of depression and ICD frequently coincide even though they are related to seemingly contrasting limbic CSTC circuit activation states. The aim of this review is to provide an overview of the currently available literature on the neurobiology of PD-related depression and ICD and discusses possible susceptibility factors. Finally, we propose a neurobiological model that identifies ventral striatal dopaminergic denervation as a common underlying neurobiological substrate of depression and ICD and subsequent dysfunction of reward and motivation-related brain areas.

Keywords: Animal studies; Brain imaging; Depression; Dopamine; Impulse control disorders; Non-motor symptoms; Parkinson's disease.

Publication types

  • Review

MeSH terms

  • Animals
  • Brain / drug effects
  • Brain / physiopathology
  • Depressive Disorder / drug therapy
  • Depressive Disorder / physiopathology*
  • Disruptive, Impulse Control, and Conduct Disorders / drug therapy
  • Disruptive, Impulse Control, and Conduct Disorders / physiopathology*
  • Dopamine / metabolism
  • Dopamine Agents / adverse effects
  • Dopamine Agents / therapeutic use
  • Humans
  • Models, Neurological
  • Parkinson Disease / drug therapy
  • Parkinson Disease / physiopathology*
  • Parkinson Disease / psychology*

Substances

  • Dopamine Agents
  • Dopamine